141 related articles for article (PubMed ID: 28446908)
1. Association of CTLA-4 Gene Variants with Response to Therapy and Long-term Survival in Metastatic Melanoma Patients Treated with Ipilimumab: An Italian Melanoma Intergroup Study.
Queirolo P; Dozin B; Morabito A; Banelli B; Piccioli P; Fava C; Leo C; Carosio R; Laurent S; Fontana V; Ferrucci PF; Martinoli C; Cocorocchio E; Battaglia A; Ascierto PA; Capone M; Simeone E; De Galitiis F; Pagani E; Antonini Cappellini GC; Marchetti P; Guida M; Tommasi S; Mandalà M; Merelli B; Quaglino P; Fava P; Guidoboni M; Romani M; Spagnolo F; Pistillo MP
Front Immunol; 2017; 8():386. PubMed ID: 28446908
[TBL] [Abstract][Full Text] [Related]
2. A novel multiplex pyrosequencing assay for genotyping functionally relevant CTLA-4 polymorphisms: potential applications in autoimmunity and cancer.
Banelli B; Morabito A; Laurent S; Piccioli P; Dozin B; Ghio M; Ascierto PA; Monteghirfo S; Marasco A; Ottaviano V; Queirolo P; Romani M; Pistillo MP
Hum Immunol; 2014 Aug; 75(8):730-9. PubMed ID: 24801647
[TBL] [Abstract][Full Text] [Related]
3. Association of CTLA-4 polymorphisms with improved overall survival in melanoma patients treated with CTLA-4 blockade: a pilot study.
Queirolo P; Morabito A; Laurent S; Lastraioli S; Piccioli P; Ascierto PA; Gentilcore G; Serra M; Marasco A; Tornari E; Dozin B; Pistillo MP
Cancer Invest; 2013 Jun; 31(5):336-45. PubMed ID: 23641913
[TBL] [Abstract][Full Text] [Related]
4. Soluble CTLA-4 as a favorable predictive biomarker in metastatic melanoma patients treated with ipilimumab: an Italian melanoma intergroup study.
Pistillo MP; Fontana V; Morabito A; Dozin B; Laurent S; Carosio R; Banelli B; Ferrero F; Spano L; Tanda E; Ferrucci PF; Martinoli C; Cocorocchio E; Guida M; Tommasi S; De Galitiis F; Pagani E; Antonini Cappellini GC; Marchetti P; Quaglino P; Fava P; Osella-Abate S; Ascierto PA; Capone M; Simeone E; Romani M; Spagnolo F; Queirolo P;
Cancer Immunol Immunother; 2019 Jan; 68(1):97-107. PubMed ID: 30311027
[TBL] [Abstract][Full Text] [Related]
5. Effects of CTLA-4 Single Nucleotide Polymorphisms on Toxicity of Ipilimumab-Containing Regimens in Patients With Advanced Stage Melanoma.
de Joode K; Mora AR; van Schaik RHN; Zippelius A; van der Veldt A; Gerard CL; Läubli H; Michielin O; von Moos R; Joerger M; Levesque MP; Aeppli S; Mangana J; Mangas C; Trost N; Meyer S; Parvex SL; Mathijssen R; Metaxas Y
J Immunother; 2024 Jun; 47(5):190-194. PubMed ID: 38318726
[TBL] [Abstract][Full Text] [Related]
6. The -319C/+49G/CT60G haplotype of CTLA-4 gene confers susceptibility to rheumatoid arthritis in Mexican population.
Torres-Carrillo N; Ontiveros-Mercado H; Torres-Carrillo NM; Parra-Rojas I; Rangel-Villalobos H; Ramírez-Dueñas MG; Gutiérrez-Ureña SR; Valle Y; Muñoz-Valle JF
Cell Biochem Biophys; 2013; 67(3):1217-28. PubMed ID: 23703660
[TBL] [Abstract][Full Text] [Related]
7. Corrigendum: Association of CTLA-4 Gene Variants with Response to Therapy and Long-term Survival in Metastatic Melanoma Patients Treated with Ipilimumab: An Italian Melanoma Intergroup Study.
Queirolo P; Dozin B; Morabito A; Banelli B; Piccioli P; Fava C; Leo C; Carosio R; Laurent S; Fontana V; Ferrucci PF; Martinoli C; Cocorocchio E; Battaglia A; Ascierto PA; Capone M; Simeone E; De Galitiis F; Pagani E; Antonini Cappellini GC; Marchetti P; Guida M; Tommasi S; Mandalà M; Merelli B; Quaglino P; Fava P; Guidoboni M; Romani M; Spagnolo F; Pistillo MP
Front Immunol; 2018; 9():403. PubMed ID: 29531523
[TBL] [Abstract][Full Text] [Related]
8. Anti-CTLA-4 based therapy elicits humoral immunity to galectin-3 in patients with metastatic melanoma.
Wu X; Giobbie-Hurder A; Connolly EM; Li J; Liao X; Severgnini M; Zhou J; Rodig S; Hodi FS
Oncoimmunology; 2018; 7(7):e1440930. PubMed ID: 29900046
[TBL] [Abstract][Full Text] [Related]
9. Prognostic factors and outcomes in metastatic uveal melanoma treated with programmed cell death-1 or combined PD-1/cytotoxic T-lymphocyte antigen-4 inhibition.
Heppt MV; Heinzerling L; Kähler KC; Forschner A; Kirchberger MC; Loquai C; Meissner M; Meier F; Terheyden P; Schell B; Herbst R; Göppner D; Kiecker F; Rafei-Shamsabadi D; Haferkamp S; Huber MA; Utikal J; Ziemer M; Bumeder I; Pfeiffer C; Schäd SG; Schmid-Tannwald C; Tietze JK; Eigentler TK; Berking C
Eur J Cancer; 2017 Sep; 82():56-65. PubMed ID: 28648699
[TBL] [Abstract][Full Text] [Related]
10. A CT60G>A polymorphism in the CTLA-4 gene of the recipient may confer susceptibility to acute graft versus host disease after allogeneic hematopoietic stem cell transplantation.
Karabon L; Markiewicz M; Partyka A; Pawlak-Adamska E; Tomkiewicz A; Dzierzak-Mietla M; Kyrcz-Krzemien S; Frydecka I
Immunogenetics; 2015 Jun; 67(5-6):295-304. PubMed ID: 25940108
[TBL] [Abstract][Full Text] [Related]
11. Influence of cytotoxic T-lymphocyte antigen-4 polymorphisms on acute rejection onset of cadaveric renal transplants.
Canossi A; Aureli A; Delreno F; Iesari S; Cervelli C; Clemente K; Famulari A; Pisani F; Papola F
Transplant Proc; 2013 Sep; 45(7):2645-9. PubMed ID: 24034013
[TBL] [Abstract][Full Text] [Related]
12. CTLA-4, CD28, and ICOS gene polymorphism associations with non-small-cell lung cancer.
Karabon L; Pawlak E; Tomkiewicz A; Jedynak A; Passowicz-Muszynska E; Zajda K; Jonkisz A; Jankowska R; Krzakowski M; Frydecka I
Hum Immunol; 2011 Oct; 72(10):947-54. PubMed ID: 21669243
[TBL] [Abstract][Full Text] [Related]
13. CTLA-4 +49A>G polymorphism of recipients of HLA-matched sibling allogeneic stem cell transplantation is associated with survival and relapse incidence.
Piccioli P; Balbi G; Serra M; Morabito A; Lamparelli T; Gobbi M; Laurent S; Dozin B; Bruzzi P; Ferraris AM; Bacigalupo A; Notaro R; Pistillo MP
Ann Hematol; 2010 Jun; 89(6):613-8. PubMed ID: 20020126
[TBL] [Abstract][Full Text] [Related]
14. Phase II study of vemurafenib followed by ipilimumab in patients with previously untreated BRAF-mutated metastatic melanoma.
Amin A; Lawson DH; Salama AK; Koon HB; Guthrie T; Thomas SS; O'Day SJ; Shaheen MF; Zhang B; Francis S; Hodi FS
J Immunother Cancer; 2016; 4():44. PubMed ID: 27532019
[TBL] [Abstract][Full Text] [Related]
15. CD28/CTLA-4/ICOS haplotypes confers susceptibility to Graves' disease and modulates clinical phenotype of disease.
Pawlak-Adamska E; Frydecka I; Bolanowski M; Tomkiewicz A; Jonkisz A; Karabon L; Partyka A; Nowak O; Szalinski M; Daroszewski J
Endocrine; 2017 Jan; 55(1):186-199. PubMed ID: 27638540
[TBL] [Abstract][Full Text] [Related]
16. Objective responses can be obtained by CTLA-4 inhibition in metastatic melanoma after BRAF inhibitor failure.
Schreuer MS; Chevolet IL; Jansen YJ; Seremet TC; Wilgenhof S; Liénard D; Del Marmol V; Neyns B
Melanoma Res; 2015 Feb; 25(1):68-74. PubMed ID: 25396684
[TBL] [Abstract][Full Text] [Related]
17. Clinical Significance of Circulating CD33+CD11b+HLA-DR- Myeloid Cells in Patients with Stage IV Melanoma Treated with Ipilimumab.
Sade-Feldman M; Kanterman J; Klieger Y; Ish-Shalom E; Olga M; Saragovi A; Shtainberg H; Lotem M; Baniyash M
Clin Cancer Res; 2016 Dec; 22(23):5661-5672. PubMed ID: 27178742
[TBL] [Abstract][Full Text] [Related]
18. Clinical Activity of Ipilimumab in Acral Melanoma: A Retrospective Review.
Johnson DB; Peng C; Abramson RG; Ye F; Zhao S; Wolchok JD; Sosman JA; Carvajal RD; Ariyan CE
Oncologist; 2015 Jun; 20(6):648-52. PubMed ID: 25964307
[TBL] [Abstract][Full Text] [Related]
19. Genetic variations in cytotoxic T-lymphocyte antigen-4 and susceptibility to cervical cancer.
Xiong YH; He L; Fei J
Int Immunopharmacol; 2014 Jan; 18(1):71-6. PubMed ID: 24201079
[TBL] [Abstract][Full Text] [Related]
20. Association studies of CTLA-4, CD28, and ICOS gene polymorphisms with B-cell chronic lymphocytic leukemia in the Polish population.
Suwalska K; Pawlak E; Karabon L; Tomkiewicz A; Dobosz T; Urbaniak-Kujda D; Kuliczkowski K; Wolowiec D; Jedynak A; Frydecka I
Hum Immunol; 2008 Mar; 69(3):193-201. PubMed ID: 18396212
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
